Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Eurofins Scientific SE is a global leader in bioanalytical testing services, specializing in food, environment, and pharmaceutical testing. With a presence in over 50 countries and a comprehensive portfolio of more than 200,000 analytical methods, Eurofins leverages its extensive laboratory network to provide high-quality, timely services that meet stringent regulatory standards.
Eurofins generates revenue by providing a wide range of testing services that cater to various industries, including food safety, pharmaceutical development, and environmental monitoring. The company's competitive advantages stem from its extensive network of laboratories, proprietary testing methods, and strong relationships with regulatory bodies, allowing it to command premium pricing and maintain high margins.
Regulatory changes impacting food and pharmaceutical testing requirements
Expansion into emerging markets such as Asia-Pacific and Latin America
Acquisitions of smaller testing laboratories to enhance service offerings
Technological advancements in testing methodologies
Regulatory changes that could impose stricter testing standards or affect market access
Technological disruption from new testing methods or competitors
Increased competition from emerging laboratory service providers
Potential price pressure from larger competitors with greater economies of scale
High debt levels relative to equity could pose risks if cash flows decline
Liquidity risks if free cash flow generation does not meet expectations
moderate - Eurofins' business is somewhat insulated from economic downturns due to the essential nature of its testing services, but overall demand may be impacted by consumer spending trends.
Interest rates affect Eurofins primarily through the cost of financing for acquisitions and capital expenditures. Higher rates could increase borrowing costs, potentially impacting expansion plans and profitability.
minimal - Eurofins operates with a manageable debt level, and its cash flow generation supports its financing needs.
growth - investors are likely attracted to Eurofins for its consistent revenue growth and expansion opportunities in the testing market.
moderate - Eurofins has a beta of approximately 1.2, indicating slightly higher volatility compared to the broader market.